<DOC>
	<DOCNO>NCT00002755</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know treatment regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness standard cyclophosphamide , methotrexate , fluorouracil high-dose combination chemotherapy plus peripheral stem cell transplantation treat woman stage II stage IIIA breast cancer .</brief_summary>
	<brief_title>Standard Chemotherapy Compared With High-Dose Combination Chemotherapy Peripheral Stem Cell Transplantation Treating Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy high dose cyclophosphamide thiotepa peripheral blood stem cell support vs conventional cyclophosphamide , methotrexate , fluorouracil ( CMF ) , follow doxorubicin induction , woman high risk breast cancer . OUTLINE : This randomize , multicenter study . Patients stratify number positive axillary node ( 4-9 v least 10 ) center . Patients randomize one two treatment arm . Arm I : Patients receive induction therapy consist doxorubicin IV every 3 week 4 course follow consolidation therapy consist cyclophosphamide IV , methotrexate IV , fluorouracil IV every 3 week 8 course . At week 4 consolidation therapy , patient receive radiotherapy breast , chest wall , axilla 3-5 week appropriate . Following recovery consolidation therapy , patient receive maintenance therapy consist oral tamoxifen daily 5 year . Arm II : Patients receive induction therapy arm I follow consolidation therapy consist stem cell mobilization high dose cyclophosphamide IV 2 hour filgrastim ( G-CSF ) subcutaneously begin 24 hour cyclophosphamide continue blood count recover . At 13-28 day follow peripheral blood stem cell ( PBSC ) collection and/or autologous bone marrow collection , patient undergo chemoablation consist thiotepa IV cyclophosphamide IV continuously 4 day follow 72 hour later PBSC infusion without autologous bone marrow . Following hematologic recovery , patient receive radiotherapy maintenance therapy arm I . Patients follow every 6 month 2 year , annually . PROJECTED ACCRUAL : More 600 patient accrue study 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage II IIIA breast cancer least 4 positive axillary node Definitive resection require , preferably within 4 week prior entry No overt residual axillary nodal carcinoma surgery Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 0 1 Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hemoglobin great 9 g/dL PT aPTT normal Hepatic : Bilirubin normal ( unless benign congenital hyperbilirubinemia ) Normal liver biopsy require patient active hepatitis B C Renal : Creatinine normal Cardiovascular : No active heart disease Normal wall motion MUGA echocardiogram Other : Adequate nutritional status ( i.e. , 1,000 calories/day orally ) HIV negative No serious medical psychiatric disease No second malignancy except : Basal cell skin cancer Carinoma situ cervix Not pregnant Negative pregnancy test PRIOR CONCURRENT THERAPY : At least 2 week since major surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>